These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29573247)

  • 21. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
    Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.
    Wang L; Chandrasekaran V; Domachowske JB; Li P; Innis BL; Jain VK
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):170-9. PubMed ID: 26407273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
    Langley JM; Carmona Martinez A; Chatterjee A; Halperin SA; McNeil S; Reisinger KS; Aggarwal N; Huang LM; Peng CT; Garcia-Sicilia J; Salamanca de la Cueva I; Cabañas F; Treviño-Garza C; Rodríguez-Weber MA; de la O M; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    J Infect Dis; 2013 Aug; 208(4):544-53. PubMed ID: 23847058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
    Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
    Wang SY; Liu SZ; Chu K; Zhao Y; Zhu FC; Hu YM; Meng FY; Li JX; Luo L; Yang JY; Liu P; Yu J
    Expert Rev Vaccines; 2017 Nov; 16(11):1155-1169. PubMed ID: 28870140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.
    Song JY; Cheong HJ; Lee J; Wie SH; Park KH; Kee SY; Jeong HW; Kim YS; Noh JY; Choi WS; Park DW; Sohn JW; Kim WJ
    Hum Vaccin Immunother; 2014; 10(10):2958-64. PubMed ID: 25483462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
    Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
    Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
    Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
    Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
    Hartvickson R; Cruz M; Ervin J; Brandon D; Forleo-Neto E; Dagnew AF; Chandra R; Lindert K; Mateen AA
    Int J Infect Dis; 2015 Dec; 41():65-72. PubMed ID: 26585940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Chang CY; Cho CY; Lai CC; Lu CY; Chang LY; Hung MC; Huang LM; Wu KG
    Vaccine; 2020 May; 38(22):3839-3846. PubMed ID: 32284272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
    Langley JM; Wang L; Aggarwal N; Bueso A; Chandrasekaran V; Cousin L; Halperin SA; Li P; Liu A; McNeil S; Mendez LP; Rivera L; Innis BL; Jain VK
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):242-51. PubMed ID: 26336604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
    Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
    Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
    [No Abstract]   [Full Text] [Related]  

  • 40. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.